InflammationNCT05439590
Impact of Cottonseed Oil on Oxidative Stress, Inflammation, and Metabolism
A study testing High dose CSO, Low dose CSO and Low dose OO in people with Inflammation and Healthy, run by Montana State University at 1 site in United States.
Trial summary
Recent research evidence suggests that cottonseed oil (CSO) may have both direct and indirect anti-inflammatory and anti-oxidative impacts linked to bioactive components of CSO and favorable alterations in lipid metabolism. Read more about this study
- Who is it for?
- Ages 18 to 55 yearsHealthy volunteers can take part
- Conditions the study is for
- Inflammation, Healthy, Oxidative Stress
- What is being tested?
- High dose CSO, Low dose CSO and Low dose OO
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 47 participants
- Where
- 1 siteUnited States
- Study dates
- 8 Aug 2022to 3 Nov 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 55 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- are between the ages of 18-55 years
- have body mass index between 18-27 kg/m2
Who cannot join
- take medications to lower cholesterol, lipids, and/or inflammation,
- take blood pressure medications,
- take antioxidant supplements (Vitamin E or C or iron) at levels greater than 800 IU/day,
- have diabetes, a gallbladder condition, or have had gallbladder removed,
- take oral contraceptives regularly,
- have smoked in the past 30 days,
Show all 12Show fewer
- consume alcohol more than 14 drinks/week,
- have an allergy to dairy, egg, tree nuts, peanuts, shellfish, soy, fish, wheat, legumes, extra virgin olive oil, and cottonseed oil, or have been on a ketogenic or paleo diet in the past six weeks,
- pregnant or lactating,
- on weight loss diet or planning to change exercise regimen,
- have physical mobility issues or are not able to walk on a treadmill,
- or have other health concerns or conditions that may interfere with your participation in the study
Trial locations and contacts
1 site in 1 country.
United States1 site
Nutrition Research Laboratory
Bozeman, Montana, 59717
About this study
Official title: The Dose-response Effect of a Four-week Intervention of Low and High Dose of Cottonseed Oil on Exercise-induced Oxidative Stress, Inflammation, and Metabolism in Healthy Adults
Recent research evidence suggests that cottonseed oil (CSO) may have both direct and indirect anti-inflammatory and anti-oxidative impacts linked to bioactive components of CSO and favorable alterations in lipid metabolism. These impacts are directly related to non-communicable diseases such as diabetes, cardiovascular diseases, and cancer. Our overarching hypothesis is that the effect of CSO consumption on oxidative stress markers (isoprostanes), inflammatory cytokines, metabolic biomarkers, and bile acid metabolism will be beneficial for reversing disease pathophysiology linked to oxidative stress, inflammation, and bile acids. Our long-term goal is to establish effective and practical therapeutic strategies utilizing dietary incorporation of CSO to prevent or reverse these diseases.
The following hypotheses will be tested in the proposed investigation:
Read more
H1: CSO consumption will lower exercise-induced oxidative stress, and the effect of CSO will be greater than that of OO for lowering of exercise-induced oxidative stress.
H2: CSO consumption will lower inflammatory cytokines and metabolic markers linked to the inflammation process in human participants, and the effect of CSO will be greater than that of OO for lowering inflammation.
H3: Features of serum bile acids, serum metabolomes, and lipidomes distinguishing CSO and OO treatment correspond to metabolic pathways illuminating the health benefits of CSO treatment.
H4: Metabolic and inflammatory impacts of dietary oils will be greater for 60 g/d of CSO compared to 30 g/d.
Read the detailed description
The approach will be to enroll a population of healthy individuals (n=32) in a four-armed (30 g CSO, 30 g OO, 60 g CSO, and 60 g OO), randomized, double-blind, parallel controlled trial to compare the effect of these different doses of oils on exercise-induced oxidative stress.
During Visit 1, participants will undergo informed consent, anthropometric measurements, and a sub-maximal exercise test to determine their VO2max. Participants will also fill Global physical activity questionnaire (GPAQ), exercise readiness questionnaire (2022-PARQ+), AHA/ACSM Health/Fitness Facility Pre-participation Screening Questionnaire, and menstruation-related questionnaire. There will be a minimum of three days run-in periods between Visit 1 and Visit 2, during which participants will be asked to follow certain dietary guidelines such as minimal use of oil, limiting the fatty fish, omega-3, vitamin A, vitamin C, vitamin A supplements, and limiting the consumption of nuts/nut seeds/oils/oilseeds or foods containing these components. During Visit 2, participants will do an exercise test (75% VO2max for 30 mins), and a blood draw will be done before and after the exercise test. Blood will be drawn after 15 minutes of the exercise test. In addition, participants will be asked to do one month diet history questionnaire and 24 hours of dietary recall. There will be four weeks between Visit 2 and Visit 3, during which period participants will be asked to consume smoothies containing respective doses of oils every day. We will provide smoothies every week, and an additional oil will be provided in an aluminum-foil-wrapped squirt bottle for participants to substitute with their regular oil. In addition, participants will be asked to fill out a compliance check form to confirm their compliance with the study diet. There will be one weekly question on gastrointestinal issues in the compliance form. After four weeks of dietary intervention, participants will come to the lab for Visit 3. Visit 3 will follow a similar protocol to Visit 2 except that the anthropometric measurements will be done in Visit 3 as well.
Procedures:
Exercise test: During Visit 1, a sub-maximal exercise test will be done to predict how much oxygen the participant's body is able to use during exercise. This allows the researchers to have one participant exercise at the same submaximal percent of his/her maximum as all of the other participants, based on his/her fitness level. This will begin with walking on a treadmill (Woodway GmbH D79576, Weil am Rhein, Denmark) for 5 minutes at a self-selected comfortable speed at 0% grade to warm up before the test. The test involves a series of stages that get increasingly more difficult every two minutes. Participants will wear a heart rate monitor, breathe through a mouthpiece that is connected to an analyzer, and wear a nose clip. The test begins with walking, and as the participant move to more difficult stages, the intensity is increased by increasing grade and speed. The researcher will end the test when the participant has reached 85% of their age-predicted maximal heart rate (220-age in years). During visits 2 and 3, participants will report to the laboratory after an overnight fast, and blood samples will be collected before and after an exercise test. The exercise test will involve a brisk uphill walk at 75% VO2max for 30 minutes on a treadmill. During exercise, a metabolic measurement system (ParvoMedics TrueMax 2400 Metabolic System, Sandy, Utah, USA) will be used to determine a respiratory quotient and the associated level of fat oxidation. The respiratory quotient will be measured by determining the volume of carbon dioxide released over the volume of oxygen absorbed during respiration. After the blood collection, TG (and full lipid panel plus glucose) will be analyzed in real-time using a clinical chemistry analyzer (Piccolo press). At the same time, serum samples will be aliquoted and stored at -80 C until analysis for inflammatory cytokines (a profile of established mediators and biomarkers), insulin, other metabolic biomarkers linked to inflammation, and the lipidomics and metabolomics analysis. For the analysis of isoprostanes, serum samples will be snap-frozen in dry ice and ethanol slurry after it is aliquoted and immediately stored at -80 C. Investigators will measure inflammatory cytokines (TNF-α, interleukin (IL)-1β, IL-6, IL-7, IL-23, and granulocyte-macrophage colony-stimulating factor (GM-CF) using high-sensitivity Luminex multiplexing technology (Bio-Rad Bio-Plex 200 HTS) prepared by Millipore.
Dietary intervention: A registered dietitian will prepare a study diet (smoothies) which will be given to participants for four weeks. Participants will be given smoothies containing either 30 g CSO, 30 g OO, 60 g CSO, or 60 g OO per day in two separate containers. The 30 g smoothies (both CSO and OO) contain 762 kcal Calories, 120 g Carbohydrates, 3 g Protein, and 30 g Fat. The 60 g smoothies (both CSO and OO) contain 761 kcal Calories, 50 g Carbohydrates, 3 g Protein, and 30 g Fat. During these four weeks period, participants will be asked to follow certain dietary guidelines and will be asked to fill out a compliance form. Participants will be asked to fill out the compliance check form daily, indicating how much smoothie they consumed and if they consumed anything not recommended by the research team. Smoothies will be given weekly, meaning participants will visit the lab every seven days to pick up their smoothies and drop off the weekly compliance form.
Metabolomic analysis: When all samples have been collected, the serum samples will be thawed, and a metabolite fraction will be extracted. After extraction, the samples will be explored using mass spectrometry analysis. An initial targeted analysis will focus on bile acids and a set of inflammation and oxidative stress biomarkers including 8-isoPGF2a. Targeted analytes will be quantified using standard curves and the resulting concentrations will be compared using several statistical analysis tools. A deep untargeted analysis will also be undertaken which may reveal additional metabolic pathways modulated by CSO consumption. Metabolite samples will be analyzed using a Waters Synapt G2Si QTOF (Waters Corporation). This instrument has ion mobility capability and can differentiate closely related compounds, such as bile acids, in complex mixtures based on their cross-sectional area and mass. The high sensitivity and variety of scan modes make the Synapt QTOF the optimal choice for untargeted analysis of complex biological samples.
Dietary analysis: Long-term dietary habits may create adaptations that influence the response to the short-term supplementation of CSO and OO. This study will use the most recent version (2018) of the web-based Diet History Questionnaire (DHQ III), a food frequency questionnaire designed for adults 19 and older, developed by staff at the Risk Factor Monitoring and Methods Branch (RFMMB) of the NIH National Cancer Institute. The outputs of the DHQ III include carbohydrate constituents, carotenoids and tocopherols, dietary constituents from supplements, fats, fatty acids and cholesterol, macronutrients and energy, minerals, protein constituents, and vitamins are dietary constituents and food groups available in the DHQ III output files. In addition, acute dietary consumption will be determined using the free, web-based Automated Self-Administered 24-hour (ASA24®) questionnaire.
Statistical test: H1 will be tested using analysis of variance (ANOVA) to compare the differences in exercise-induced oxidative stress markers (isoprostanes) among the individuals consuming either 30 g CSO, 30g OO, or 60 g CSO, or 60 g OO. H2 will be tested using analysis of variance (ANOVA) to compare the differences in inflammation and inflammatory markers among the individuals consuming either 30 g CSO, 30g OO, 60 g CSO, or 60 g OO. To test H3, the investigator will identify changes in serum bile acids and metabolomes and then determine the metabolic pathways associated with the metabolic changes to identify potential mechanisms underlying the health impacts of CSO. To test H4, the investigator will identify the measure of serum isoprostanes, bile acids, inflammation, lipidomes, and metabolomes, and then use regression analysis to determine the level of variability in response to the different doses of CSO and OO.
- Conditions
- Inflammation, Healthy, Oxidative Stress, Metabolic Syndrome
- Being tested
- High dose CSO, Low dose CSO, Low dose OO, High dose OO
- Medical subject headings
- Inflammation, Metabolic Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
High dose CSOBehavioural
Also called HD CSO
Participants in the high-dose CSO arm of the study will consume two smoothies containing a total of 60 g of CSO per day for 4 weeks.
Low dose CSOBehavioural
Also called LD CSO
Participants in the low-dose CSO arm of the study will consume two smoothies containing a total of 30 g of CSO per day for 4 weeks.
Low dose OOBehavioural
Also called LD OO
Participants in the low-dose OO arm of the study will consume two smoothies containing a total of 30 g of OO per day for 4 weeks.
High dose OOBehavioural
Also called HD OO
Participants in the high-dose OO arm of the study will consume two smoothies containing a total of 60 g of OO per day for 4 weeks.
| Study group | Role | What they receive |
|---|---|---|
| High dose CSO | Experimental | Participants will be randomly assigned to a smoothie containing 60 g of CSO per day for four weeks.They will be asked to consume smoothies any time of the day. Receives: Behavioral: High dose CSO |
| Low dose CSO | Experimental | Participants will be randomly assigned to a smoothie containing 30 g of CSO per day for four weeks.They will be asked to consume smoothies any time of the day. Receives: Behavioral: Low dose CSO |
| High dose OO | Active comparator | Participants will be randomly assigned to a smoothie containing 60 g of OO per day for four weeks.They will be asked to consume smoothies any time of the day. Receives: Behavioral: High dose OO |
| Low dose OO | Active comparator | Participants will be randomly assigned to a smoothie containing 30 g of OO per day for four weeks.They will be asked to consume smoothies any time of the day. Receives: Behavioral: Low dose OO |
What is being measured
The primary outcome is the main question the study is designed to answer.
Serum oxidative stress biomarkers
Concentration of exercise-induced serum isoprostanes (nM/L)
Measured: 4 weeks
Fasting serum bile acid concentration
Concentration of fasting serum bile acids (nM/L)
Measured: 4 weeks
Fasting serum lipids
Concentration of fasting serum triglycerides, high density lipoproteins, cholesterol, very low density cholesterol (mM)
Measured: 4 weeks
Fasting serum inflammatory cytokines
Concentration of fasting serum inflammatory cytokine responses (tumor necrosis factor-alpha, interleukin-(IL)1beta, IL-6, IL-10, IL-17, IL-23, interferon-gamma, and granulocyte macrophage-colony stimulating factor; all in pg/ml)
Measured: 4 weeks
Fasting serum lipidome and metabolome features (Untargeted)
Serum lipidomes and metabolomes features (Untargeted measured using LC-MS)
Measured: 4 weeks
Fasting glucose
Serum glucose concentration (mM)
Measured: 4 weeks
Fasting insulin
Serum insulin concentration (microIU/mL)
Measured: 4 weeks
Fasting Eicosanoids
Several serum prostaglandins, leukotrienes, and thromboxanes (nM)
Measured: 4 weeks
Secondary outcomes (5)
Body composition
% body fat
Measured: 4 weeks
Visceral Adipose Tissue
Quantity of adipose in liters located within the abdominal compartment
Measured: 4 weeks
Body Mass Index
kg of body mass per meter of height squared
Measured: 4 weeks
Blood Pressure
Systolic and Diastolic blood pressure measured in mmHg
Measured: 4 weeks
Aerobic Fitness
VO2max measured in mL/kg/min
Measured: 1 day
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Jun 2022
- Study start8 Aug 2022
- Primary completion3 Nov 2023
- Study completion3 Nov 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for InflammationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- The design is randomized parallel design, where the healthy adults will be randomized into 30 g CSO, 30 g OO, 60 g CSO, and 60 g OO.
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 47 participants (actual)
Sponsor and investigators
- Lead sponsor
- Montana State University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Mary P. Miles, PhD, Principal investigator, Montana State University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05439590
- Sponsor's protocol ID
- Cotton Incorporated 22-070
- Status last verified
- Nov 2023
- First submitted
- 27 Jun 2022
- Last updated
- 18 Nov 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Nov 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Dose-response Effect of a Four-week Intervention of Low and High Dose of Cottonseed Oil on Exercise-induced Oxidative Stress, Inflammation, and Metabolism in Healthy Adults
- ClinicalTrials.gov ID
- NCT05439590
- Acronym / sponsor ID
- Cotton Incorporated 22-070
- Conditions
- Inflammation, Healthy, Oxidative Stress, Metabolic Syndrome
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 47 participants (actual)
- Lead sponsor
- Montana State UniversityUniversity, hospital or other
- Study start
- 8 Aug 2022 (actual)
- Primary completion
- 3 Nov 2023 (actual)
- Study completion
- 3 Nov 2023 (actual)
- First posted
- 30 Jun 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Recent research evidence suggests that cottonseed oil (CSO) may have both direct and indirect anti-inflammatory and anti-oxidative impacts linked to bioactive components of CSO and favorable alterations in lipid metabolism. These impacts are directly related to non-communicable diseases such as diabetes, cardiovascular diseases, and cancer. Our overarching hypothesis is that the effect of CSO consumption on oxidative stress markers (isoprostanes), inflammatory cytokines, metabolic biomarkers, and bile acid metabolism will be beneficial for reversing disease pathophysiology linked to oxidative stress, inflammation, and bile acids. Our long-term goal is to establish effective and practical therapeutic strategies utilizing dietary incorporation of CSO to prevent or reverse these diseases.
The following hypotheses will be tested in the proposed investigation:
H1: CSO consumption will lower exercise-induced oxidative stress, and the effect of CSO will be greater than that of OO for lowering of exercise-induced oxidative stress.
H2: CSO consumption will lower inflammatory cytokines and metabolic markers linked to the inflammation process in human participants, and the effect of CSO will be greater than that of OO for lowering inflammation.
H3: Features of serum bile acids, serum metabolomes, and lipidomes distinguishing CSO and OO treatment correspond to metabolic pathways illuminating the health benefits of CSO treatment.
H4: Metabolic and inflammatory impacts of dietary oils will be greater for 60 g/d of CSO compared to 30 g/d.
Detailed description
The approach will be to enroll a population of healthy individuals (n=32) in a four-armed (30 g CSO, 30 g OO, 60 g CSO, and 60 g OO), randomized, double-blind, parallel controlled trial to compare the effect of these different doses of oils on exercise-induced oxidative stress.
During Visit 1, participants will undergo informed consent, anthropometric measurements, and a sub-maximal exercise test to determine their VO2max. Participants will also fill Global physical activity questionnaire (GPAQ), exercise readiness questionnaire (2022-PARQ+), AHA/ACSM Health/Fitness Facility Pre-participation Screening Questionnaire, and menstruation-related questionnaire. There will be a minimum of three days run-in periods between Visit 1 and Visit 2, during which participants will be asked to follow certain dietary guidelines such as minimal use of oil, limiting the fatty fish, omega-3, vitamin A, vitamin C, vitamin A supplements, and limiting the consumption of nuts/nut seeds/oils/oilseeds or foods containing these components. During Visit 2, participants will do an exercise test (75% VO2max for 30 mins), and a blood draw will be done before and after the exercise test. Blood will be drawn after 15 minutes of the exercise test. In addition, participants will be asked to do one month diet history questionnaire and 24 hours of dietary recall. There will be four weeks between Visit 2 and Visit 3, during which period participants will be asked to consume smoothies containing respective doses of oils every day. We will provide smoothies every week, and an additional oil will be provided in an aluminum-foil-wrapped squirt bottle for participants to substitute with their regular oil. In addition, participants will be asked to fill out a compliance check form to confirm their compliance with the study diet. There will be one weekly question on gastrointestinal issues in the compliance form. After four weeks of dietary intervention, participants will come to the lab for Visit 3. Visit 3 will follow a similar protocol to Visit 2 except that the anthropometric measurements will be done in Visit 3 as well.
Procedures:
Exercise test: During Visit 1, a sub-maximal exercise test will be done to predict how much oxygen the participant's body is able to use during exercise. This allows the researchers to have one participant exercise at the same submaximal percent of his/her maximum as all of the other participants, based on his/her fitness level. This will begin with walking on a treadmill (Woodway GmbH D79576, Weil am Rhein, Denmark) for 5 minutes at a self-selected comfortable speed at 0% grade to warm up before the test. The test involves a series of stages that get increasingly more difficult every two minutes. Participants will wear a heart rate monitor, breathe through a mouthpiece that is connected to an analyzer, and wear a nose clip. The test begins with walking, and as the participant move to more difficult stages, the intensity is increased by increasing grade and speed. The researcher will end the test when the participant has reached 85% of their age-predicted maximal heart rate (220-age in years). During visits 2 and 3, participants will report to the laboratory after an overnight fast, and blood samples will be collected before and after an exercise test. The exercise test will involve a brisk uphill walk at 75% VO2max for 30 minutes on a treadmill. During exercise, a metabolic measurement system (ParvoMedics TrueMax 2400 Metabolic System, Sandy, Utah, USA) will be used to determine a respiratory quotient and the associated level of fat oxidation. The respiratory quotient will be measured by determining the volume of carbon dioxide released over the volume of oxygen absorbed during respiration. After the blood collection, TG (and full lipid panel plus glucose) will be analyzed in real-time using a clinical chemistry analyzer (Piccolo press). At the same time, serum samples will be aliquoted and stored at -80 C until analysis for inflammatory cytokines (a profile of established mediators and biomarkers), insulin, other metabolic biomarkers linked to inflammation, and the lipidomics and metabolomics analysis. For the analysis of isoprostanes, serum samples will be snap-frozen in dry ice and ethanol slurry after it is aliquoted and immediately stored at -80 C. Investigators will measure inflammatory cytokines (TNF-α, interleukin (IL)-1β, IL-6, IL-7, IL-23, and granulocyte-macrophage colony-stimulating factor (GM-CF) using high-sensitivity Luminex multiplexing technology (Bio-Rad Bio-Plex 200 HTS) prepared by Millipore.
Dietary intervention: A registered dietitian will prepare a study diet (smoothies) which will be given to participants for four weeks. Participants will be given smoothies containing either 30 g CSO, 30 g OO, 60 g CSO, or 60 g OO per day in two separate containers. The 30 g smoothies (both CSO and OO) contain 762 kcal Calories, 120 g Carbohydrates, 3 g Protein, and 30 g Fat. The 60 g smoothies (both CSO and OO) contain 761 kcal Calories, 50 g Carbohydrates, 3 g Protein, and 30 g Fat. During these four weeks period, participants will be asked to follow certain dietary guidelines and will be asked to fill out a compliance form. Participants will be asked to fill out the compliance check form daily, indicating how much smoothie they consumed and if they consumed anything not recommended by the research team. Smoothies will be given weekly, meaning participants will visit the lab every seven days to pick up their smoothies and drop off the weekly compliance form.
Metabolomic analysis: When all samples have been collected, the serum samples will be thawed, and a metabolite fraction will be extracted. After extraction, the samples will be explored using mass spectrometry analysis. An initial targeted analysis will focus on bile acids and a set of inflammation and oxidative stress biomarkers including 8-isoPGF2a. Targeted analytes will be quantified using standard curves and the resulting concentrations will be compared using several statistical analysis tools. A deep untargeted analysis will also be undertaken which may reveal additional metabolic pathways modulated by CSO consumption. Metabolite samples will be analyzed using a Waters Synapt G2Si QTOF (Waters Corporation). This instrument has ion mobility capability and can differentiate closely related compounds, such as bile acids, in complex mixtures based on their cross-sectional area and mass. The high sensitivity and variety of scan modes make the Synapt QTOF the optimal choice for untargeted analysis of complex biological samples.
Dietary analysis: Long-term dietary habits may create adaptations that influence the response to the short-term supplementation of CSO and OO. This study will use the most recent version (2018) of the web-based Diet History Questionnaire (DHQ III), a food frequency questionnaire designed for adults 19 and older, developed by staff at the Risk Factor Monitoring and Methods Branch (RFMMB) of the NIH National Cancer Institute. The outputs of the DHQ III include carbohydrate constituents, carotenoids and tocopherols, dietary constituents from supplements, fats, fatty acids and cholesterol, macronutrients and energy, minerals, protein constituents, and vitamins are dietary constituents and food groups available in the DHQ III output files. In addition, acute dietary consumption will be determined using the free, web-based Automated Self-Administered 24-hour (ASA24®) questionnaire.
Statistical test: H1 will be tested using analysis of variance (ANOVA) to compare the differences in exercise-induced oxidative stress markers (isoprostanes) among the individuals consuming either 30 g CSO, 30g OO, or 60 g CSO, or 60 g OO. H2 will be tested using analysis of variance (ANOVA) to compare the differences in inflammation and inflammatory markers among the individuals consuming either 30 g CSO, 30g OO, 60 g CSO, or 60 g OO. To test H3, the investigator will identify changes in serum bile acids and metabolomes and then determine the metabolic pathways associated with the metabolic changes to identify potential mechanisms underlying the health impacts of CSO. To test H4, the investigator will identify the measure of serum isoprostanes, bile acids, inflammation, lipidomes, and metabolomes, and then use regression analysis to determine the level of variability in response to the different doses of CSO and OO.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 4
- Model description
- The design is randomized parallel design, where the healthy adults will be randomized into 30 g CSO, 30 g OO, 60 g CSO, and 60 g OO.
| Arm | Type | Receives |
|---|---|---|
| High dose CSO | Experimental | Behavioral: High dose CSOParticipants will be randomly assigned to a smoothie containing 60 g of CSO per day for four weeks.They will be asked to consume smoothies any time of the day. |
| Low dose CSO | Experimental | Behavioral: Low dose CSOParticipants will be randomly assigned to a smoothie containing 30 g of CSO per day for four weeks.They will be asked to consume smoothies any time of the day. |
| High dose OO | Active comparator | Behavioral: High dose OOParticipants will be randomly assigned to a smoothie containing 60 g of OO per day for four weeks.They will be asked to consume smoothies any time of the day. |
| Low dose OO | Active comparator | Behavioral: Low dose OOParticipants will be randomly assigned to a smoothie containing 30 g of OO per day for four weeks.They will be asked to consume smoothies any time of the day. |
Who may qualify
- Ages
- 18 to 55 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (2 listed)
- are between the ages of 18-55 years
- have body mass index between 18-27 kg/m2
Key exclusion criteria (12 listed)
- take medications to lower cholesterol, lipids, and/or inflammation,
- take blood pressure medications,
- take antioxidant supplements (Vitamin E or C or iron) at levels greater than 800 IU/day,
- have diabetes, a gallbladder condition, or have had gallbladder removed,
- take oral contraceptives regularly,
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| High dose CSOAlso: HD CSOParticipants in the high-dose CSO arm of the study will consume two smoothies containing a total of 60 g of CSO per day for 4 weeks. | Behavioural | High dose CSO |
| Low dose CSOAlso: LD CSOParticipants in the low-dose CSO arm of the study will consume two smoothies containing a total of 30 g of CSO per day for 4 weeks. | Behavioural | Low dose CSO |
| Low dose OOAlso: LD OOParticipants in the low-dose OO arm of the study will consume two smoothies containing a total of 30 g of OO per day for 4 weeks. | Behavioural | Low dose OO |
| High dose OOAlso: HD OOParticipants in the high-dose OO arm of the study will consume two smoothies containing a total of 60 g of OO per day for 4 weeks. | Behavioural | High dose OO |
Primary outcome
Serum oxidative stress biomarkers
Time frame: 4 weeks
Concentration of exercise-induced serum isoprostanes (nM/L)
Fasting serum bile acid concentration
Time frame: 4 weeks
Concentration of fasting serum bile acids (nM/L)
Fasting serum lipids
Time frame: 4 weeks
Concentration of fasting serum triglycerides, high density lipoproteins, cholesterol, very low density cholesterol (mM)
Fasting serum inflammatory cytokines
Time frame: 4 weeks
Concentration of fasting serum inflammatory cytokine responses (tumor necrosis factor-alpha, interleukin-(IL)1beta, IL-6, IL-10, IL-17, IL-23, interferon-gamma, and granulocyte macrophage-colony stimulating factor; all in pg/ml)
Fasting serum lipidome and metabolome features (Untargeted)
Time frame: 4 weeks
Serum lipidomes and metabolomes features (Untargeted measured using LC-MS)
Fasting glucose
Time frame: 4 weeks
Serum glucose concentration (mM)
Fasting insulin
Time frame: 4 weeks
Serum insulin concentration (microIU/mL)
Fasting Eicosanoids
Time frame: 4 weeks
Several serum prostaglandins, leukotrienes, and thromboxanes (nM)
5 secondary outcomes
Body composition
Time frame: 4 weeks
Visceral Adipose Tissue
Time frame: 4 weeks
Body Mass Index
Time frame: 4 weeks
Blood Pressure
Time frame: 4 weeks
Aerobic Fitness
Time frame: 1 day
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Nov 2023.
- Individual participant dataSharing planned: No
Related trials for Inflammation
Not yet recruitingPhase 2/3
A Pivotal Safety and Immunogenicity GBS-NN/NN2 Vaccine Maternal Immunisation Trial
Streptococcus Agalactiae Infection, Neonatal Sepsis
RecruitingPhase 1
Pilot Study to Identify the Mediators and Inflammatory Cell Surface Receptors Involved in Allergic Airway Inflammation
Asthma
RecruitingPhase 4
Lidocaine Infiltration and Neuroimmunomodulation in Head and Neck Cancer Surgery
Head and Neck Cancer (H&N)
Active, not recruiting
CT for Personalized Mechanical Ventilation
Ventilator-Induced Lung Injury, Sepsis Syndrome
RecruitingPhase 4
A Study to Compare the Efficacy and Safety of Extended and Intermittent Infusion of Beta-lactams in Critically Ill Paediatric Patients
Infection, Sepsis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Mary P. Miles, PhD principal investigator
Montana State University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing High dose CSO, Low dose CSO and Low dose OO in people with Inflammation and Healthy, run by Montana State University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 Nov 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Serum oxidative stress biomarkers (time frame: 4 weeks). The study lists 8 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Nov 2023.